Condition
Pain Associated With Fibromyalgia
Total Trials
5
Recruiting
0
Active
0
Completed
5
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
80%
4 trials in Phase 3/4
Results Transparency
100%
5 of 5 completed with results
Key Signals
5 with results100% success
Data Visualizations
Phase Distribution
4Total
P 3 (4)
Trial Status
Completed5
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT01773993CompletedPrimary
Special Investigation of Pregabalin for Fibromyalgia (Regulatory Post Marketing Commitment Plan)
NCT02187159Phase 3CompletedPrimary
Treatment of Pain Associated With Fibromyalgia
NCT02187471Phase 3CompletedPrimary
Treatment of Pain Associated With Fibromyalgia
NCT02146430Phase 3CompletedPrimary
Treatment of Pain Associated With Fibromyalgia
NCT02234583Phase 3CompletedPrimary
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Showing all 5 trials